# Abionyx Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abionyx-pharma

- Industry: Pharmaceuticals
- Headquarters: France
- Website: www.cerenis.com
- Total disclosed funding: $82M
- Latest round: Series C (Nov 16, 2010)
- Investors on record: 13

## About

Abionyx Pharma specializes in the development of innovative therapies aimed at addressing cardiovascular and metabolic diseases through proprietary biopharmaceutical products.Founded in 2005 by Jean-Louis Dasseux, Abionyx Pharma is based in France and focuses on creating therapeutics for critical health conditions. The company has undergone various strategic pivots but currently operates independently without subsidiaries. The firm has raised a total of USD 4.12 mn through PIPE funding, with its most recent deal occurring on March 26, 2015, indicating a targeted investment approach.Abionyx Pharma is dedicated to developing advanced biopharmaceutical products for the treatment of cardiovascular and metabolic disorders. Its pipeline includes various proprietary compounds designed to improve patient outcomes in these therapeutic areas and is aimed at healthcare professionals and institutions seeking innovative treatment options.In 2022, Abionyx Pharma reported zero revenue, with an EBITDA of USD -5,407,545.70 for the year 2023. The company's business model primarily revolves around the development of its biopharmaceutical products, which are expected to generate revenue in future market launches as they advance through clinical trials.Moving forward, Abionyx Pharma plans to launch new products aimed at addressing unmet needs within cardiovascular and metabolic health. The company is targeting expansion into European and North American markets by 2025, leveraging recent funding of USD 4.12 mn to support its product development and market entry strategies. The firm aims to finalize product trials and begin marketing efforts in these regions, enhancing its footprint in the biopharmaceutical industry.

## Funding rounds

- Series C, Nov 16, 2010, $6.9M — IXO Private Equity, Institut Regional de Developpement Industriel
- Series C, Aug 11, 2010, $26M — OrbiMed Advisors, Sofinnova Partners, HealthCap, TVM Capital Life Science, Daiwa Corporate Investment, EDF Ventures, ACP Capital, Fonds Stratégique d' Investissement
- Series B, Dec 11, 2006, $19M — OrbiMed Advisors, Sofinnova Partners, HealthCap, TVM Capital Life Science, Daiwa Corporate Investment, EDF Ventures, ACP Capital, SMBC Capital Partners
- Series A, Sep 21, 2005, $30M — Alta Partners, Sofinnova Partners, HealthCap, Daiwa Corporate Investment, EDF Ventures, REI Ventures

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B, Series C
- HealthCap — Series A, Series B, Series C
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series A, Series B, Series C
- EDF Ventures (https://capitalatlas.ai/funds/edf-ventures) — Series A, Series B, Series C
- REI Ventures — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series B, Series C
- ACP Capital — Series B, Series C
- SMBC Capital Partners (https://capitalatlas.ai/funds/smbc-capital-partners) — Series B
- Fonds Stratégique d' Investissement — Series C
- IXO Private Equity (https://capitalatlas.ai/funds/ixo-private-equity) — Series C
- Institut Regional de Developpement Industriel — Series C